Leveraging the central dogma of biology to treat disease has been a therapeutic aim for decades. Mitigating symptoms and offering better outcomes by using nucleic acids as medicines promises new treatment options for neurodegenerative and hereditary diseases previously thought to be incurable with traditional pharmaceutical modalities. Antisense oligonucleotides (ASOs) are single stranded sequences capable of modifying mRNA structure and activity, preventing aberrant protein translation.

The mechanism of action for ASOs may be elegant, but development and scaling from R&D to cGMP manufacturing can be complex. Adapting small-scale production and analytical methods used in a research lab to cGMP environments can prove difficult. Getting tech transfer from Process Development to cGMP settings right the first time is critical. Improper documentation of methods and use of different analytical equipment may require costly and time-consuming rework and revalidation.

Our Danaher Life Sciences companies provide a wide range of analytical solutions and fit-for-purpose technologies to accelerate ASO development. We can enable seamless tech transfer to manufacturing and offer technologies flexible to both upstream and cGMP environments.

Antisense Oligonucleotides Solutions

To learn more about solutions provided by Danaher Life Sciences companies visit: